2257 — Sirnaomics Share News
0.000.00%
Last trade - 00:00- HK$504.72m
- HK$357.54m
Brief: Sirnaomics Says Michael V. Molyneaux To Resign As An Executive Director
Brief: Sirnaomics Presents Positive Clinical Data Of STP705 For Focal Fat Reduction
Brief: Sirnaomics Announces Strategic Partnership With Edirna Inc
Brief: Sirnaomics Enters Into Stock Purchase Agreement And License & Option Agreement With Edirna Inc
Brief: Sirnaomics Reports Interim Results Of STP705 Phase I Clinical Study
Brief: Sirnaomics Dosed First Patient In Phase I Clinical Study Of Galnac-Based Rnai Therapeutic Stp122g For Anticoagulant Treatment
Brief: Sirnaomics To Receive HK$8 Million Subsidy From The HKSTP Clinical Translational Catalyst Plan
Brief: RNAimmune Receives FDA Clearance Of Investigational New Drug Application For Phase 1 Trial Of RV-1730 COVID-19 Booster Vaccine
Brief: Sirnaomics Receives Regulatory Clearance On IND Application From U.S. FDA
Brief: Sirnaomics Receives IND Clearance From FDA For Phase I Clinical Study Of RNAI Therapeutic
Brief: Sirnaomics Says Loss For The Year $97.4 Mln
Brief: Sirnaomics Says As Of March 10, Total Cash Of $3.3 Million In Account Maintained With SVB
Brief: Sirnaomics Says Unit Made Initial Subscription For A Segregated Portfolio
Brief: Sirnaomics Announces Interim Data From Phase I Clinical Trial Of Rnai Therapeutic Stp707 For Treatment Of Multiple Solid Tumors
Brief: Sirnaomics Announces Positive Interim Data From Phase Iib Clinical Trial Of Stp705 In Adults With Cutaneous Squamous Cell Carcinoma In Situ
Brief: Sirnaomics Says Yip Wing Kei Appointed As Chief Financial Officer Of Group
Brief: Sirnaomics Doses The First Patient In Phase I Clinical Trial Of RNAi Therapeutic STP705 In Adults Undergoing Abdominoplasty For Medical Aesthetics Treatment
Brief: Sirnaomics Posts HY Loss $46.1 Million
Brief: Sirnaomics Ltd Says Advances Galaheadtm-Based RNAI Therapeutics